An inhibitor of DPP-IV could stimulate the secretion of insulin by improving the activity, which significantly improved symptoms in type 2 diabetes.22 The level of GLP-1 in plasma is associated with the activity of DPP-IV. This evidence concerns the gene INS and type 2 diabetes mellitus.